← Retour au Screener

Sector: Santé
Open in Terminal → FTRELive chart · Key metrics · News · Smart money

Fortrea Holdings Inc.

FTRE Small Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

13,35 €
-0.07% aujourd'hui
52W: 3,80 € – 16,28 €
52W Low: 3,80 € Position: 76.5% 52W High: 16,28 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
14.22x
P/E prévisionnel
P/S Ratio
0.53x
Cours/Ventes
EV/EBITDA
35.52x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,3 Md €
Capitalisation boursière
Croissance du CA
-2.3%
Croissance du CA sur un an
Marge bénéficiaire
-16.5%
Marge nette
ROE
-64.55%
Rentabilité des capitaux propres
Beta
2.11
Sensibilité au marché
Positions vendeuses
11.79%
% du flottant vendu à découvert
Volume moyen
1,298,869
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
11 analysts
Avg. Price Target
14,13 €
+5.87% upside
Target Range
8,28 € – 17,44 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 14,000 Exchange: NMS

Fortrea Holdings Inc. en bref

Fortrea Holdings Inc. (FTRE) is currently trading at 13,35 € with a market capitalization of 1,3 Md €. The 52-week range spans from 3,80 € to 16,28 €; the current price is 18% below the yearly high. Year-over-year revenue growth stands at -2.3%.

💰 Dividende

Fortrea Holdings Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Fortrea Holdings Inc. (FTRE) au consensus : Acheter. L'objectif de cours moyen est de 14,13 €, soit un potentiel de +5.87% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 8,28 € à 17,44 €.

Fortrea Holdings Inc. : la thèse d'investissement en détail

Fortrea Holdings Inc. (FTRE) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -2.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 212.7% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

With a PEG ratio of 0.34, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 35.52x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Buy
  • Free cash flow positif
Points faibles
  • CA en contraction (-2.3% sur un an)
  • Actuellement non rentable
  • Endettement élevé (D/E 212.7)
  • Forte volatilité (Bêta 2.11)
  • Positions vendeuses élevées (11.79%)

Aperçu technique

MM 50 jours
11,59 €
+15.11% vs. cours
MM 200 jours
10,83 €
+23.27% vs. cours
Sous le plus haut 52s
−18%
16,28 €
Au-dessus du plus bas 52s
+251.1%
3,80 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
2.11 · Élevé
Évolue plus que le marché global
Positions vendeuses
11.79% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
212.7 · Élevé
Dette totale / capitaux propres

The data points to above-average price swings, elevated short interest (11.79%), higher leverage relative to equity.

Trading Data

50-Day MA: 11,59 €
200-Day MA: 10,83 €
Volume: 2,477,149
Avg. Volume: 1,298,869
Short Ratio: 6.05
P/B Ratio: 2.75x
Debt/Equity: 212.7x
Free Cash Flow: 249 M €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Fortrea Holdings Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Scroll to Top